New biotech from Alexis Borisy will test Merck KGaA, Blueprint cancer drug combo in bid to fulfill Gleevec promise
Alexis Borisy and Ben Auspitz want to be intelligent with their latest biotech, not “stupid.”
That’s in the words of Borisy, the repeat biotech entrepreneur behind the likes of Blueprint Medicines and EQRx. He and business partner Auspitz, a long-time industry investor at F-Prime Capital, want to bring together “intelligently designed” cancer drugs, hence their startup’s name: IDRx.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 164,000+ biopharma pros reading Endpoints daily — and it's free.